

25th March 2025

Dear Pharmacist,

Re: Update on Australian supply of Pegasys® (peginterferon alfa-2a)

Echo Therapeutics Pty Ltd is the registered sponsor of Pegasys® (peginterferon alfa-2a) [AUST R 91836 and 91879]. Echo Therapeutics appreciates your understanding regarding the supply of Pegasys® to your hospital. We also wanted to provide an update on the current status of local supply of Pegasys®.

Presently, we are down to just under three months supply, with no definitive timeline of when replenishment stock of Australian labelled Pegasys® will become available. This anticipated shortage is listed on the [TGA Medicines Shortages website](#). While we are hopeful that there will be no significant supply interruption, we are mitigating with options such as supplying foreign-labelled stock under section 19A of the TGA to ensure patients can continue to access treatment.

In the unlikely event of a protracted shortage, the Haematology Society of Australia and New Zealand (HSANZ) are providing information and guidance on their [HSANZ website](#) including a [video link](#) where Dr Cecily Forsyth discusses possible patient management strategies.

Echo Therapeutics believes that these treatment management strategies will help mitigate a supply interruption and will continue to keep you apprised of any developments.

Please forward this notification on to relevant members of your team to whom it would be of interest.

Should you have any questions or require additional information, please don't hesitate to contact Echo Therapeutics on 1300 848 328 or connect@echotherapeutics.net.

Kind Regards,



Jude D'Silva

Managing Director
Echo Therapeutics